Recommended Articles

1. Agostoni A, Aygören-Pürsün E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and aquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51-S131.

2. Agostoni A, Cicardi M. Hereditary and acquired C1-i nhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992;71:206 –215.

3. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy 2007: 62: 842–856.

4. Binkley KE, Davis AE III. Estrogen-dependent inherited angioedema. Transfus Apheresis Sci. 2003;29:215–219.

5. Blanch A, Roche O, Lopez-Granados E, Fontan G, Lopez-Trascasa M. Detection of C1 inhibitor (SERPING1/C1NH) mutations in exon 8 in patients with hereditary angioedema: evidence for 10 novel mutations. Hum Mutat 2002;20:405-6.

6. Bock SC, Skriver K, Nielsen E, et al. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry. 1986;25:4292– 4301.

7. Bork K, Barnstedt S. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema . Arch Intern Med. 2001;161:714-18.

8. Bork K, Barnstedt S, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356: 213-217.

9. Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med. 2003;114:294 –298.

10. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119:267–274. Bork K, Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus Apheresis Sci. 2003;29:235–238.

11. Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol 2002; 36, 707–709.

12. Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006;619 –627.

13. Bouillet L, Ponard D, Drouet C, Jullien D, Massot C. Angioedema and oral contraception. Dermatology 2003;206:106–109.

14. Bowen T, guest editor. Editorial. Transfus Apheresis Sci. 2003;29:193–194.

15. Bowen T, Cicardi M, Bork K, Farkas H, Kreutz W, Zingale L, et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol. 2008;100(Suppl 2):S30–S40.

16. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol. 2004;114:629 – 637.

17. Bowen B, Hawk JJ, Sibunka S, Hovick S, Weiler JM. A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations. Clin Immunol 2001;98:157-63.

18. Bowen T, Hebert J, Ritchie B, et al. Management of hereditary angioedema: a Canadian approach. Transfus Apheresis Sci. 2003;29: 205–214.

19. Caballero T, Lopez-Serrano C. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J Allergy Clin Immunol 2006; 117,476–477.

20. Caldwell JR, Ruddy S, Schur PH, Austen KF. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol. 1972;1:39 –52.

21. Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000;52:91-112.

22. Campos MM, Souza GE, Calixto JB. In vivo B1 kinin-receptor upregulation. Evidence for involvement of protein kinases and nuclear factor kappaB pathways. Br J Pharmacol 1999;127:1851–1859.

23. Cicardi M, Bergamaschini L, Cugno M. Beretta A, Zingale LC, Colombo M, et al. Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology. 1998;199:366 –376.

24. Cicardi M, Bergamaschini L, Marasini B, Boccassini G, Tucci A, Agostoni A. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci.1982;284:2-9.

25. Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. 1997; J. Allergy Clin. Immunol. 99, 194–196.

26. Cicardi M, Igarashi T, Rosen FS, Davis AE 3rd. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J Clin Invest 1987;79:698-702.

27. Cicardi M, Zingale L. The deficiency of C1 inhibitor and its treatment. Immunobiology 2007;212:325-31.

28. Cicardi M, Zingale LC, Pappalardo E, Falcioni A, Agostoni A. Auto-antibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore). 2003;82:274 –281.

29. Cicardi M, Zingale L, Zanichelli A, Pappalardo E, Cicardi B. C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol 2005; 27, 286–298.

30. Cugno M, Bos I, Lubbers Y, Hack CE, Agostoni A. In vitro interaction of C1-inhibitor with thrombin. Blood Coagul Fibrinolysis 2001;12: 253-60.

31. Cugno M, Cicardi M, Bottasso B, Coppola R, Paonessa R, Mannucci PM, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997;89:3213-8.

32. Davis AE. The pathogenesis of hereditary angioedema. Transfus Apheresis Sci 2003;29:195-203.

33. Davis AE. New treatments addressing the pathophysiology of hereditary angioedema. Clinical and Molecular Allergy 2008, 6:2.

34. De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert (R) P) in hereditary angioedema: a review. Transfus Apheresis Sci 2003; 29, 247–254.

35. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343:1286 –1289.

36. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C’1-esterase. Am J Med. 1963;35:37– 44.

37. Farkas H, Fust G, Fekete B, Karádi I, Varga L. Eradication of Helicobacter pylori and improvement of hereditary angionurotic oedema. Lancet 2001; 358: 1695-6.

38. Farkas H, Harmat G, Fay A, et al. Erythema marginatum preceding an acute oedematous attack of hereditary angioneurotic oedema. Acta Derm Venereol. 2001;81:376 –377.

39. Farkas H, Harmat G, Gyeney L, Fust G, Varga L. Danazol therapy for hereditary angio-oedema in children. Lancet, 1999;354:1.031-2.

40. Farkas H, Harmat G, Kaposi PN, Karádi I, Fekete B, Füst G et al. Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema. Eur J Gastroenterol Hepatol. 2001;13:1225-1230.

41. Farkas H, Varga L. The Hungarian HAE experience. Transfus Apheresis Sci. 2003;29:229 –233.

42. Farkas H, Varga L, Széplaki G, Visy B, Harmat G, Bowen T. Management of hereditary angioedema in pediatric patients. Pediatrics 2007;120(3):e713-e722.

43. Frank MM. Hereditary angioedema: a half century of progress. J Allergy Clin Immunol. 2004;3: 626-628.

44. Frank M, Gelfand JA, Alling DW, Sherins RJ. Epsilon aminocaproic acid for hereditary angioedema. N Engl J Med 1977;21:1235-6.

45. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976;84:580 –593.

46. Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 1972; 286, 808.

47. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295, 1444–1448.

48. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immnunol. 2005;139:379-394.

49. Gonzales-Quevedo T, Caballero T, Cicardi M, Bork K, Williams A. The synthetic Kunitz domain protein Dx88 to treat angioedema in patients with hereditary angioedema. Int Immunopharmacol 2002; 2, 1318.

50. Hill BJ, Thomas SH, McCabe C. Fresh frozen plasma for acute exacerbations of hereditary angioedema. Am J Emerg Med 2004; 22,633.

51. Huang SW. Results of an on line survey of patients with hereditary Angioedema. Allergy Asthma Proc 2004; 25:127—131.

52. Koles K, van Berkel PH, Pieper FR, Nuijens JH, Mannesse ML, Vliegenthart JF, et al. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology 2004;1:51-64.

53. Kunschak M, Engl W, Maritsch F, Rosen FS, Eder G, Zerlauth G, et al. A randomized, controlled trial to study the efficacy and safety of C-1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998;38:540–49.

54. Lehmann A. Ecallantide (Dyax/Genzyme). Curr Opin Invest Drugs 2006; 7,282–290.

55. Lumry W, Ritchie B, Beck T, Morrison J. Interim results of EDEMA2, a multicenter, open-label, repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88) in hereditary angioedema. J Allergy Clin Immunol 2006; 117, S179.

56. Lundh B, Laurell AB, Wetterqvist H, White T, Granerus G. A case of hereditary angioneurotic oedema, successfully treated with epsilon-aminocaproic acid: studies on C-1 esterase inhibitor, C-1 activation, plasminogen level and histamine metabolism. Clin Exp Immunol 1968;7:733-45.

57. Marasini B, Cicardi M, Martignoni GC, Agostoni A. Treatment of hereditary angioedema. Klin Wochenschr 1978;56:819-823.

58. Nielsen EW, Johansen HT, Holt J, Mollnes TE. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res. 1994;35:184 –187.

59. Nilsson IM, Andersson L, Bjorkman SE. Epsilon-aminocaproic acid (E-ACA) as a therapeutic agent based on 5 year’s clinical experience. Acta Med Scand Suppl 1966; 448:1-46.

60. Nuijens J, Verdonk R, Van Doorn M, Burggraaf K, Cohen A, Choi G, et al. Clinical studies of recombinant human C1 inhibitor in subjects with hereditary angioedema. J Allergy Clin Immunol 2005; 115, S202.

61. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998;351:1693-7.

62. Osler W. Hereditary angio-neurotic oedema. Am J Med Sci. 1888;95:362–367.

63. Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. Immunol Lett 2003; 86,271–276.

64. Pickering RJ, Kelly JR, Good RA, et al. Replacement therapy in hereditary angioedema - successful treatment of two patients with fresh frozen plasma. Lancet 1969;1:326–30.

65. Quincke H. Concerning the acute localized oedema of the skin. Monatsh Prakt Derm. 1882;1:129 –131.

66. Ritchie RH, Marsh JD, Lancaster WD, Diglio CA, Schiebinger RJ. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. Hypertension 1998;31:39–44.

67. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, Lopez-Trascasa M. Hereditary angioedema (HAE) due to C1 inhibitor deficiency: registry of the patients and approach to the prevalence in Spain. Ann Allergy Asthma Immunol. 2005;94:498–503.

68. Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981;68:181–7.

69. Sheffer AL, Fearon DT, Austen KF. Hereditary angioedema: a decade of management with stanozolol. J Allergy Clin Immunol 1987;80:855–60.

70. Theriault A, Whaley K, McPhaden AR, Boyd E, Connor JM. Regional assignment of the human C1-inhibitor gene to 11q11– q13.1. Hum Genet. 1990;84:477– 479.

71. van Doorn MB, Burggraaf J, van Dam T, Eerenberg A, Levi M et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005; 116, 876–883.

72. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29, 236–261.

73. Visy B, Fust G, Varga L, Szendei G, Takács E, Karádi I, et al. Sex hormones in hereditary angioneurotic oedema. Clin Endocrinol 2004; 60: 508-15.

74. Vogelaar EF, Brummelhuis HGJ, Krijnen HW. Contribution to the optimal use of human blood. III. Large scale preparation of human C1 esterase inhibitor concentrate for clinical use. Vox Sang 1974;26:118–27.

75. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334, 1630–1634.

76. Williams T. DX-88, a novel recombinant protein inhibitor of plasma kallikrein: safety and immunogenicity in early studies. J Allergy Clin Immunol 2005; 115, S181.

77. Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci. 2003; Dec;29(3):255-8.

78. Wuillemin WA, Eldering E, Citarella F, de Ruig CP, ten Cate H, Hack CE. Modulation of contact system proteases by glycosaminoglycans: selective enhancement of the inhibition of factor XIa. J Biol Chem 1996;271:12913-8.

79. Wuillemin WA, te Velthuis H, Lubbers YT, de Ruig CP, Eldering E, Hack CE. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol 1997;159:1953-60.

80. Zingale LC, Beltrami L, Zanichellia A, et al. Angioedema without urticaria: a large clinical survey. CMAJ. 2006;175:1065–1070.

81. Zuraw BL. Hereditary Angioedema. N Engl J Med. 2008;359:1027-36.

82. Zuraw BL, Herschbach J. Detection of C1 inhibitor mutations in patients with hereditary angioedema. J Allergy Clin Immunol 2000;105:541-6.

83. Zuraw BL, Sugimoto S, Curd JG. The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency. J Allergy Clin Immunol 1986;78:1115–1120.

Last update: 08.25.2009